Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research.

Slides:



Advertisements
Similar presentations
CE REVIEW UNDERSTANDING HYPERTENSION. Hypertension is a chronic medical condition affecting more than 65 million Americans. Controlling hypertension is.
Advertisements

ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.
Preventing Strokes One at a Time Acute Interventions and Management 2009.
The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.
JNC 8 Guidelines….
ASCOT TRIAL Abbas Zaidi 20/09/05. Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million.
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
“Influence of age on the management of heart failure: Findings from Get With the Guidelines–Heart Failure (GWTG-HF)” Daniel E. Forman, MD; Christopher.
 Currently 150 Million people worldwide suffering from diabetes and that number may double by the year  The prevalence of type 2 diabetes is dramatically.
RACIAL DISPARITIES IN PRESCRIPTION DRUG UTILIZATION AN ANALYSIS OF BETA-BLOCKER AND STATIN USE FOLLOWING HOSPITALIZATION FOR ACUTE MYOCARDIAL INFARCTION.
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.
Blood Pressure Monitoring
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Electronic Medical Record Use and the Quality of Care in Physician Offices National Conference on Health Statistics August 17, 2010 Chun-Ju (Janey) Hsiao,
Pharmacological Treatment of Hypertension Update 2012.
Lookback Module: What you should know 2012 National Conference on Health Statistics Monitoring Health Care Reform through Provider-based Surveys: New Initiatives.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Hypertension JNC VII classification * * The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High.
TRANSLATING VISITS INTO PATIENTS USING AMBULATORY VISIT DATA (Hypertensive patient case study) by Esther Hing, M.P.H. and Julia Holmes, Ph.D U.S. DEPARTMENT.
M Mohsen Ibrahim, MD CARDIOLOGY DEPARTMENT-CAIRO UNIVERSITY MINIMAL vs OPTIMAL MEDICAL CARE.
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
Systolic hypertension not an isolated problem Michael Weber, MD Professor of Medicine Associate Dean Downstate College of Medicine State University of.
Electronic Health Records and Clinical Decision Support Systems Impact on National Ambulatory Care Quality Max J. Romano, BA; Randall S. Stafford, MD,
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.
10 Points to Remember on the Assessment of Cardiovascular RiskAssessment of Cardiovascular Risk Summary Prepared by Melvyn Rubenfire, MD.
Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.
1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.
Hypertension NICE CG127 August Hypertension is not a disease it is a risk factor for cardiovasuclar disease (CVD)-it is a modifiable risk factor.
Women’s health: Data from the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS) Esther.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National Center for Health Statistics 1 Monitoring Million Hearts.
10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.
Hypertension & diabetes: new guidelines Janice Douglas, MD Case Western University Cleveland, OH George L Bakris, MD Director of the Hypertension/Clinical.
IMPACT OF AN ESSENTIAL DRUGS LIST AND TREATMENT GUIDELINES ON PRESCRIBING IN SOUTH AFRICA In 1998 the National Department of Health (NDOH) published standard.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Adult Hypertension Survey Results Mercy Medical Group, Inc. Alan R. Ertle, MD, MPH, MBA Friday, January 09, 2015.
Knowledge, Attitude and Behaviour of prescribers after the introduction of the treatment guidelines in South Africa Pillay T, Hill SR University of Newcastle.
A. Olowofela and A. O. Isah Clinical Pharmacology and Therapeutics Unit, Department of Medicine University of Benin Teaching Hospital. Benin-City. Nigeria.
HvC Comparative Effectiveness Project Groups 5 and 6
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
Thiazide diuretics, Potassium, and the Development of Diabetes A Quantitative Review Hypertension2006_219.
Innovations in Management of Cardiovascular Disease for Global Health
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
On the Health of the US Health Care System… Insights and analyses from the National Health Care Survey Irma E. Arispe, PhD Division of Health Care Statistics.
Polypill x Aspirin Project Groups 3 and 4
Is there evidence to justify different claims for different drug classes? Presentation to: Cardiovascular & Renal Drugs Advisory Committee Food & Drug.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Pre-ALLHAT Drug Use IMS Health NDTI, Year % of Treated Patients on Medication CCBs Beta Blockers Diuretics ACE Inhibitors.
1 Dissemination and Implementation Paul K. Whelton MD, MSc for the ALLHAT Collaborative Research Group ALLHAT U.S. Department of Health and Human Services.
1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Therapeutics Conference. Fluid Resuscitation Early correction of fluid deficit is essential in hypovolemic shock to prevent decline in tissue perfusion.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Evidence based medicine Antihypertensive drugs in the elderly Group 1 and 6 -Heba Othman -Heba Sabry -Reem Ahmed -Dina Reda -Dalia El Magraby.
Management of Hypertension according to JNC 7
Hypertension guidelines What’s all the controversy about 2015
JNC VIII Hypertension.
Hypertension JNC VIII Guidelines.
Copyright © 2007 American Medical Association. All rights reserved.
Exercise Adherence in Patients with Diabetes: Evaluating the role of psychosocial factors in managing diabetes Natalie N. Young,1, 2 Jennifer P. Friedberg,1,
Hypertension treatment guidelines from the United Kingdom’s National Institute for Health and Care Excellence. Guidelines identify angiotensin-converting.
Managing Complex Hypertension: What Every Physician Should Know
Managing Hard-To-Treat Hypertension: What Every Physician Should Know
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Beth Wallace, BSN, RN-BC, FNP-S Fairfield University Summer 2010
Pharmacological Treatment of Hypertension Update 2012
Presentation transcript:

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE National Trends in the Prescribing of Anti-Hypertensive Medications Jun Ma, MD, PhD Research Associate Mentor: Randall Stafford, MD, PhD Program on Prevention Outcomes and Practices

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Background  Practice guidelines aim to guide physician practice according to the best available evidence  Process of translating national guidelines and clinical evidence into public health benefit is complex  Past studies suggest that guidelines are not necessarily being followed

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Background  Diffusion of information from latest guidelines and clinical trial findings is suboptimal  Despite the promise of new findings, adoption patterns may not always serve patients:  Use of medications lacking evidence of benefit  Failure to use drugs with the strongest evidence  Suggestion that sizable increase in drug costs has not provided a public health benefit

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Antihypertensive Prescribing : Magnitude of the Problem  Elevated blood pressure is a major risk factor for heart diseases and stroke – leading causes of death in the U.S.  About 50 million Americans have elevated blood pressure with continued increases expected  Antihypertensive medications cost $15 billion annually (10% of drug costs)

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Objective  Examine the impact of JNC guidelines on antihypertensive prescribing by physicians in private practice and hospital outpatient clinics

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Guidelines for HTN Treatment Joint National Commission (JNC) on Prevention, Detection, Evaluation and Treatment of High Blood Pressure  JNC V recommendations (1993)  Diuretics and β-blockers should be used as preferred first-line medications  JNC VI recommendations (1997)  Diuretics and/or β-blockers should be used as first-line agents unless specific comorbidities compel selection of other drugs

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Data Sources  U.S. ambulatory care surveys by National Center for Health Statistics  National Ambulatory Medical Care Survey (NAMCS) Nationally representative sample of patient visits to office-based physicians  National Hospital Ambulatory Medical Care Survey (NHAMCS) Nationally representative sample of patient visits to hospital outpatient departments (OPDs)

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Data Sources  Multistage probability sampling procedures  NAMCS: PSU  Physicians  Patient Visits  NHAMCS: PSU  Hospitals  OPDs  Visits  Annual participation rates  NAMCS: 63-73% of selected physicians  NHAMCS: 94-98% of selected hospitals  Physician/staff-recorded information on standard patient encounter forms

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Study Sample  Hypertensive visits: patient visits having a principal diagnosis of essential HTN  Sample size: (namcs)/ (nhamcs)  National estimates: 23-49M/18-37M  Antihypertensive drug visits: hypertensive visits in which at least 1 antihypertensive drug was mentioned  % of hypertensive visits: 65-80%

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Antihypertensive Medication Classes  Diuretics: thiazides vs. other diuretics  Beta/Alpha-Beta Blockers  Calcium Antagonists  ACE Inhibitors  Angiotensin Receptor Blockers (ARBs)  Alpha Blockers  Central-Acting Alpha-Agonists  Direct Vasodilators

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Trends in Antihypertensive Prescribing, NAMCS JNC VJNC VI

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Trends in Antihypertensive Prescribing, NHAMCS JNC VJNC VI

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Trends in Prescribing of Diuretics, NAMCS JNC VJNC VI

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Trends in Prescribing of Diuretics, NHAMCS JNC VJNC VI

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Differences in Prescribing of Diuretics, NAMCS and NHAMCS Diuretics Sex (ref: Female) Male0.65 ( ) Race (ref: White) African American1.53 ( ) Age (ref: y) ( ) 1.47 ( ) 1.73 ( ) Time (ref: ‘93-’97) ’98-’ ( )

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Differences in Prescribing of  - Blockers, NAMCS and NHAMCS  -Blocker Sex (ref: Female) Male0.89 ( ) Race (ref: White) African American0.74 ( ) Age (ref: y) ( ) 0.88 ( ) 0.86 ( ) Time (ref: ‘93-’97) ’98-’ ( )

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Guidelines for HTN Treatment Joint National Commission (JNC) on Prevention, Detection, Evaluation and Treatment of High Blood Pressure  JNC VII recommendations (2003)  Thiazide diuretics should be initial choice either alone or in combination with drugs of other classes  ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) ( Dec 2002 )  Thiazide diuretics are at least as effective as the more expensive ACE inhibitors and CCBs in lowering blood pressure as well as cardiovascular events

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE IMS Health Data  National Disease and Therapeutic Index  Nationally-based random sample of patient visits to office-based physicians  Physician-reported data on new and continuing medications for each diagnosis per patient visit  Annual sample size for HTN averaged 20,000

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Most Recent Trends in Antihypertensive Prescribing ALLHATJNC VII

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Summary of Results  Changes in antihypertensive prescribing are generally consistent with JNC recommendations and clinical evidence  Increased prescribing of thiazide diuretics  Increased prescribing of  -blockers  Declined prescribing of CCBs and more recently of ACE inhibitors

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Summary of Results  Thiazides remain under prescribed despite most favorable cost-effectiveness  Immediate upswing in thiazides following the ALLHAT publication in December 2002 did not sustain  Impact of clinical evidence alone can be short-lived  Efforts needed to encourage widespread adoption of evidence-based medicine

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Summary of Results  CCBs and ACE inhibitors remain the most frequently prescribed antihypertensive drug classes  Increasing popularity of ARBs  More recent market entry and associated intense advertising

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Limitations  Visit-based data may not reflect proportions of use in general population  Lack of data necessary to assess treatment appropriateness at individual level  Lack of data on patient compliance and outcomes

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Implications  Need to foster more timely and complete dissemination of evidence-based guidelines  Need to address physician adherence barriers  Lack of awareness or familiarity with guidelines  Lack of agreement with recommendations  Attractiveness of new therapies and pressure to use the latest therapy

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE Implications  Need to shift focus from reducing blood pressure (single risk factor) to prevention of CVD (absolute risk)  Need to assess the impact of evidence in the context of other factors that can influence prescribing practices

Stanford Prevention Research Center STANFORD SCHOOL OF MEDICINE